These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
2. Association of Transthyretin Val122Ile Variant With Incident Heart Failure Among Black Individuals. Parcha V; Malla G; Irvin MR; Armstrong ND; Judd SE; Lange LA; Maurer MS; Levitan EB; Goyal P; Arora G; Arora P JAMA; 2022 Apr; 327(14):1368-1378. PubMed ID: 35377943 [TBL] [Abstract][Full Text] [Related]
3. Age Dependency of Cardiovascular Outcomes With the Amyloidogenic pV142I Transthyretin Variant Among Black Individuals in the US. Selvaraj S; Claggett BL; Quarta CC; Yu B; Inciardi RM; Buxbaum JN; Mosley TH; Shah AM; Dorbala S; Falk RH; Solomon SD JAMA Cardiol; 2023 Aug; 8(8):784-788. PubMed ID: 37212191 [TBL] [Abstract][Full Text] [Related]
4. Transthyretin V142I Genetic Variant and Cardiac Remodeling, Injury, and Heart Failure Risk in Black Adults. Coniglio AC; Segar MW; Loungani RS; Savla JJ; Grodin JL; Fox ER; Garg S; de Lemos JA; Berry JD; Drazner MH; Shah S; Hall ME; Shah A; Khan SS; Mentz RJ; Pandey A JACC Heart Fail; 2022 Feb; 10(2):129-138. PubMed ID: 35115086 [TBL] [Abstract][Full Text] [Related]
5. The amyloidogenic V122I transthyretin variant in elderly black Americans. Quarta CC; Buxbaum JN; Shah AM; Falk RH; Claggett B; Kitzman DW; Mosley TH; Butler KR; Boerwinkle E; Solomon SD N Engl J Med; 2015 Jan; 372(1):21-9. PubMed ID: 25551524 [TBL] [Abstract][Full Text] [Related]
6. Prospective evaluation of the morbidity and mortality of wild-type and V122I mutant transthyretin amyloid cardiomyopathy: the Transthyretin Amyloidosis Cardiac Study (TRACS). Ruberg FL; Maurer MS; Judge DP; Zeldenrust S; Skinner M; Kim AY; Falk RH; Cheung KN; Patel AR; Pano A; Packman J; Grogan DR Am Heart J; 2012 Aug; 164(2):222-228.e1. PubMed ID: 22877808 [TBL] [Abstract][Full Text] [Related]
7. Association of the V122I Hereditary Transthyretin Amyloidosis Genetic Variant With Heart Failure Among Individuals of African or Hispanic/Latino Ancestry. Damrauer SM; Chaudhary K; Cho JH; Liang LW; Argulian E; Chan L; Dobbyn A; Guerraty MA; Judy R; Kay J; Kember RL; Levin MG; Saha A; Van Vleck T; Verma SS; Weaver J; Abul-Husn NS; Baras A; Chirinos JA; Drachman B; Kenny EE; Loos RJF; Narula J; Overton J; Reid J; Ritchie M; Sirugo G; Nadkarni G; Rader DJ; Do R JAMA; 2019 Dec; 322(22):2191-2202. PubMed ID: 31821430 [TBL] [Abstract][Full Text] [Related]
8. Cardiovascular Disease and Mortality in Black Women Carrying the Amyloidogenic V122I Transthyretin Gene Variant. Haring B; Hunt RP; Shadyab AH; Eaton C; Kaplan R; Martin LW; Panjrath G; Kuller LH; Assimes T; Kooperberg C; Wassertheil-Smoller S JACC Heart Fail; 2023 Sep; 11(9):1189-1199. PubMed ID: 36930136 [TBL] [Abstract][Full Text] [Related]
9. Relation of clinical, echocardiographic and electrocardiographic features of cardiac amyloidosis to the presence of the transthyretin V122I allele in older African-American men. Jacobson D; Tagoe C; Schwartzbard A; Shah A; Koziol J; Buxbaum J Am J Cardiol; 2011 Aug; 108(3):440-4. PubMed ID: 21600538 [TBL] [Abstract][Full Text] [Related]
10. Association of Low Plasma Transthyretin Concentration With Risk of Heart Failure in the General Population. Greve AM; Christoffersen M; Frikke-Schmidt R; Nordestgaard BG; Tybjærg-Hansen A JAMA Cardiol; 2021 Mar; 6(3):258-266. PubMed ID: 33237279 [TBL] [Abstract][Full Text] [Related]
11. Cardiovascular Risk Factors and Genetic Risk in Transthyretin V142I Carriers. Shetty NS; Gaonkar M; Pampana A; Patel N; Morrison AC; Reiner AP; Carson AP; Yu B; Psaty BM; Kooperberg C; Fatkin D; Boerwinkle E; Rotter JI; Taylor KD; Hou L; Irvin MR; Hall ME; Maurer M; Fornage M; Armstrong ND; Bart N; Goyal P; Rich SS; Vasan RS; Li P; Arora G; Arora P JACC Heart Fail; 2024 Oct; ():. PubMed ID: 39520444 [TBL] [Abstract][Full Text] [Related]
12. Association of APOL1 With Heart Failure With Preserved Ejection Fraction in Postmenopausal African American Women. Franceschini N; Kopp JB; Barac A; Martin LW; Li Y; Qian H; Reiner AP; Pollak M; Wallace RB; Rosamond WD; Winkler CA JAMA Cardiol; 2018 Aug; 3(8):712-720. PubMed ID: 29971324 [TBL] [Abstract][Full Text] [Related]
13. Identification of Transthyretin Cardiac Amyloidosis Using Serum Retinol-Binding Protein 4 and a Clinical Prediction Model. Arvanitis M; Koch CM; Chan GG; Torres-Arancivia C; LaValley MP; Jacobson DR; Berk JL; Connors LH; Ruberg FL JAMA Cardiol; 2017 Mar; 2(3):305-313. PubMed ID: 28196196 [TBL] [Abstract][Full Text] [Related]
14. Cardiac Amyloidosis Due to Transthyretin Protein: A Review. Ruberg FL; Maurer MS JAMA; 2024 Mar; 331(9):778-791. PubMed ID: 38441582 [TBL] [Abstract][Full Text] [Related]
15. Sex and Race Differences in Lifetime Risk of Heart Failure With Preserved Ejection Fraction and Heart Failure With Reduced Ejection Fraction. Pandey A; Omar W; Ayers C; LaMonte M; Klein L; Allen NB; Kuller LH; Greenland P; Eaton CB; Gottdiener JS; Lloyd-Jones DM; Berry JD Circulation; 2018 Apr; 137(17):1814-1823. PubMed ID: 29352072 [TBL] [Abstract][Full Text] [Related]
16. Heart Failure Risk Among African-American Women With an ICAM1 Missense Variant. Dalal PJ; Giro P; Rasmussen-Torvik LJ; Yancy CW; Shah SJ; Reiner AP; Haring B; Martin LW; Wells GL; Manson JE; Kooperberg C; Eaton CB; Patel RB JACC Heart Fail; 2024 Sep; 12(9):1614-1624. PubMed ID: 38530700 [TBL] [Abstract][Full Text] [Related]
18. Variant-sequence transthyretin (isoleucine 122) in late-onset cardiac amyloidosis in black Americans. Jacobson DR; Pastore RD; Yaghoubian R; Kane I; Gallo G; Buck FS; Buxbaum JN N Engl J Med; 1997 Feb; 336(7):466-73. PubMed ID: 9017939 [TBL] [Abstract][Full Text] [Related]
19. Transthyretin V122I (pV142I)* cardiac amyloidosis: an age-dependent autosomal dominant cardiomyopathy too common to be overlooked as a cause of significant heart disease in elderly African Americans. Buxbaum JN; Ruberg FL Genet Med; 2017 Jul; 19(7):733-742. PubMed ID: 28102864 [TBL] [Abstract][Full Text] [Related]
20. Estimated 5-Year Number Needed to Treat to Prevent Cardiovascular Death or Heart Failure Hospitalization With Angiotensin Receptor-Neprilysin Inhibition vs Standard Therapy for Patients With Heart Failure With Reduced Ejection Fraction: An Analysis of Data From the PARADIGM-HF Trial. Srivastava PK; Claggett BL; Solomon SD; McMurray JJV; Packer M; Zile MR; Desai AS; Rouleau JL; Swedberg K; Fonarow GC JAMA Cardiol; 2018 Dec; 3(12):1226-1231. PubMed ID: 30484837 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]